trending Market Intelligence /marketintelligence/en/news-insights/trending/32F6C1PWnNgGUAKA3MdkYw2 content esgSubNav
In This List

Silence Therapeutics blood disorder drug gets EU orphan drug tag

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Silence Therapeutics blood disorder drug gets EU orphan drug tag

Silence Therapeutics PLC said its SLN124 medicine was granted the orphan drug designation by the European Medicines Agency for treating beta-thalassemia, a blood disorder.

The designation — which grants the therapy expedited clinical development and 10 years of exclusivity if approved — was given by the EMA's Committee for Orphan Medicinal Products.

Beta-thalassemia is an inherited blood disorder that reduces the production of hemoglobin, the protein in red blood cells that transports oxygen throughout the body.

London-based Silence is developing SLN124 for treating iron overload disorders such as beta-thalassemia, myelodysplastic syndrome and hereditary hemochromatosis. Iron overload disorders are characterized by the accumulation of iron in the body.